Correction

Article Outline

• Copyright

The article, “Metabolites of progesterone and the pregnane X receptor: A novel pathway regulating uternine contractibility in pregnancy?” by Mitchell et al, published in the April 2005 (Volume 192, p 1304-15) contains an error in Table I. The corrected table appears below.

Table I. Inhibitory activity on oxytocin-induced contractions in rat myometrium in vitro and binding affinity for PXR for metabolites of progesterone

Steroid	Inhibition at 100 μM∗	PXR activation†
DMSO (control)	98.8 ± 1.6	—
4-pregnen-3,20-dione (progesterone)‡	45.0 ± 5.0	1.2
4-pregnen-20α-ol,3-one‡	63.4 ± 6.1	1.3
4-pregnen-20β-ol,3-one‡	40.9 ± 8.2	0.3
5-pregnen-3β-ol, 20-one (pregnenolone)	91.3 ± 5.5	2.3
5α-pregnan-20α-ol,3-one	75.2 ± 9.2	6.7
5α-pregnan-3α-ol,20-one‡	67.7 ± 7.1	6.8
5α-pregnan-3α,20β-diol	61.4 ± 11.4	1.4
5α-pregnan-3β,20α-diol	90.2 ± 11.1	14.5
5β-pregnan-3,20-dione‡	28.0 ± 7.9	2.5
5β-pregnan-20α-ol,3-one‡	32.0 ± 10.0	4.2
5β-pregnan-3α-ol,20-one‡	50.4 ± 9.7	3.3
5β-pregnan-3β-ol,20-one‡	49.6 ± 7.3	1.7
5β-pregnan-3α,20α-diol	85.6 ± 2.0	8.1
5β-pregnan-3α,20β-diol	93.5 ± 13.0	1.1
5β-pregnan-3β,20α-diol‡	25.2 ± 5.9	2.0
5β-pregnan-3β,20β-diol‡	23.7 ± 5.3	0.7
RU486 (mifepristone, n=1)	19.5	1.2